Basic Information
| Drug ID | DDPD09119 |
|
| Drug Name | Eslicarbazepine acetate | |
| Molecular Weight | 296.326 | |
| Molecular Formula | C17H16N2O3 | |
| CAS Number | 236395-14-5 | |
| SMILES | CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 | |
| External Links | ||
| DRUGBANK | DB09119 | |
| PubChem Compound | 179344 | |
| PDR | 3400 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 8.8 | - | 8.8 | - | # Bialer M, Soares-da-Silva P: Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012 Jun;53(6):935-46. doi: 10.1111/j.1528-1167.2012.03519.x. Epub 2012 May 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22612290 |
| Water Solubility | 4200.0 | mg/L | 4.2 | mg/ml | # Banach M, Borowicz KK, Czuczwar SJ: Pharmacokinetic/pharmacodynamic evaluation of eslicarbazepine for the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2015 Apr;114):639-48. doi: 10.1517/17425255.2015.1021686. Epub 2015 Mar 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/25740561 |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| T Max | 2.5 | h | 1-4 | h | DRUGBANK | |
| Clearance | 1.2 | L/h | 20.0 | ml/min | Renal clearance; normal renal function; | DRUGBANK |
| Volume of Distribution | 61.3 | L | 61.3 | L | Apparent volume of distribution; | DRUGBANK |
| Half-life | 15.0 | h | 10-20 | h | elimination half-life; normal,healthy; rheumatoid arthritis; | DRUGBANK | Half-life | 16.5 | h | 13-20 | h | elimination half-life; epilepsy; | DRUGBANK |
| Protein Binding | 40.0 | % | <40 | % | plasma proteins; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 1200.0 | mg/day | 1200 | mg/day | PO, oral | Aptiom | eslicarbazepine acetate | PDR |
| Max dose for children | 900.0 | mg/day | 900 | mg/day | PO, oral | Aptiom | eslicarbazepine acetate | PDR |
| Max dose for children | 800.0 | mg/day | 800 | mg/day | PO, oral | Aptiom | eslicarbazepine acetate | PDR |
| Max dose for children | 600.0 | mg/day | 600 | mg/day | PO, oral | Aptiom | eslicarbazepine acetate | PDR |
| Max dose for adolescents | 1200.0 | mg/day | 1200 | mg/day | PO, oral | Aptiom | eslicarbazepine acetate | PDR |
| Max dose for adolescents | 900.0 | mg/day | 900 | mg/day | PO, oral | Aptiom | eslicarbazepine acetate | PDR |
| Max dose for adolescents | 800.0 | mg/day | 800 | mg/day | PO, oral | Aptiom | eslicarbazepine acetate | PDR |
| Max dose for adults | 1600.0 | mg/day | 1600 | mg/day | PO, oral | Aptiom | eslicarbazepine acetate | PDR |
| Max dose for geriatric | 1600.0 | mg/day | 1600 | mg/day | PO, oral | Aptiom | eslicarbazepine acetate | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1